Investigation of novel therapeutic approaches involving combinations of several anti-melanoma agents (such as dual targeting of BRAF/MEK and cyclin-dependent kinases CDK4/6) could provide significant improvement in the prognosis of BRAF-mutated metastatic melanoma patients [17,18]. The gene discussed is CDK4; the disease is melanoma.